Overview

A class action lawsuit has been filed against RxSight, Inc. (“RxSight” or the “Company”), and certain of the Company’s former senior executive officers alleging violations of the federal securities laws. RxSight’s common stock trades on the NASDAQ exchange under the symbol “RXST.”

The RxSight class action lawsuit was brought on behalf of all persons and entities who purchased or otherwise acquired RxSight securities between November 7, 2024, and July 8, 2025, both dates inclusive (the “Class Period”).

RxSight is a commercial-stage medical technology company, engaged in the research and development, manufacture, and sale of light adjustable intraocular lenses (“LAL”) used in cataract surgery in the United States. The Company’s primary product is the RxSight system, which includes the LAL and a specially designed machine for delivering light to the eye, the Light Delivery Device (“LDD”).

The RxSight lawsuit alleges that Defendants, throughout the Class Period, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company was experiencing adoption challenges and/or structural issues resulting in declines in sales and utilization; (2) Defendants had overstated the demand for RxSight’s products; (3) as a result, RxSight was unlikely to meet its own previously issued finanical guidance for fiscal year 2025; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

*          *          *

If you purchased or otherwise acquired RxSight securities between November 7, 2024, and July 8, 2025, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as lead plaintiff in the RxSight class action lawsuit is September 22, 2025.